Latest Share Chat

EVG.L Share News (EVG)

EVG.L Information

There is currently no data for EVG

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Wed, 07th Apr 2021 16:22

Evgen Pharma PLC - clinical stage drug development company - Notes that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by some variants of coronavirus. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.

"We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021," says Chief Executive Huw Jones.

Current stock price: 8.28 pence, up 1.0% on Wednesday

Year-to-date change: down 19%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

More News

24 Jan 2011 14:42

Business picking up for Evolution

Broker Evolution says that trading conditions improved towards the end of 2010. This is inline with other brokers, such as Panmure Gordon and Arden, which have released trading statements and results in recent weeks. Evolution says that there is a growing pipeline of corporate transactions. That

5 Jan 2011 08:16

Panmure Gordon boosted by US recovery

Stockbroker and investment bank Panmure Gordon has seen a significant improvement in its operating performance in the second half of the year. "Both our UK and US businesses generated operating profits in this six months, in spite of continued challenging trading conditions," it adds. UK investme

19 Nov 2010 15:31

Small caps round-up: Huntsworth, Porvair

Shares in public relations outfit Huntsworth fell back after it said some of the revenues it had expected to come in this year will be delayed until 2011. It also announced that finance director Tymon Broadhead is stepping down to be replaced by Colin Adams, currently finance boss at the Harry Pott

19 Oct 2010 17:49

No Evolution bid for Panmure

Evolution says that it has decided not to bid for fellow broker Panmure Gordon. Evolution says that it reviews Panmure's interim results and subsequently made an indicative conditional proposal to Panmure's board. That proposal was rejected and Evolution does not believe that further discussions a

15 Oct 2010 15:49

QInvest considering options for Panmure stake

It appears that Evolution may have more chance of acquiring rival broker Panmure Gordon than first thought because QInvest is rumoured to be considering selling its 44% stake in the broker. Ironically, Qatar-based investment bank QInvest has asked Lazard to advise it on its options. Lazard used to

8 Oct 2010 17:29

Evolution given Panmure bid deadline

The Takeover Panel has told broker Evolution that it has until 5pm on 28 October to make a firm bid for Panmure Gordon. Fully listed Evolution has said that it is interested in buying its AIM-quoted rival but has put no firm proposals on the table. If it does not make a bid by the deadline it will

23 Sep 2010 17:03

Evolution ponders Panmure bid

Broker and fund manager Evolution Group says that it is considering a bid for AIM-quoted broker Panmure Gordon. Evolution says that a Panmure offer is one of a number of options under consideration. No formal discussions have taken place with Panmure. Evolution says it is waiting to assess Panmu

25 Mar 2010 08:25

Record breaking year at Evolution

2009 was a record breaking year on many fronts for investment management firm Evolution Group. Group income, private client income, investment banking income and assets under management all hit new highs. Total income more than doubled to £129.4m in 2009 from £63.9m, with investment banking income

1 Feb 2010 07:39

Evolution doubles FY revenue

Investment management firm Evolution Group said it more than doubled full year revenue after a strong performance across all of its divisions in the second half. Increased activity in the second half of the year and it growing business pipeline makes the group confident full year earnings will be i

9 Nov 2009 06:18

Monday newspaper round-up: Cadbury, RBS/Lloyds, Vodafone

Kraft, the American food company, is poised to initiate a hostile takeover bid for Cadbury today at or slightly above the offer it made in September, which valued the British confectioner at £10.2bn, according to a person familiar with the deal. Last night Kraft was finalising plans to go directly

2 Nov 2009 16:30

Broking boss makes £2.6m profit

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have

30 Oct 2009 06:11

Friday tips round-up: AstraZeneca, Kazakhmys, Standard Life

AstraZeneca posted a sparkling set of third-quarter results on Thursday, sending analysts scurrying away to upgrade their numbers. Pre-tax profits rocketed by 24pc, on revenues up 5pc. On closer inspection, however, the results were flattered by a series of ?one-off gains. The Telegraph recommended

29 Oct 2009 16:23

London close: Shares end near session high

London's top stocks closed near its session high on news that the US economy grew faster than expected in the third quarter. Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years. Part-nationalised bank Lloyd

29 Oct 2009 14:55

London afternoon: Blue chips track US advance

America's return to growth in the third quarter, stronger UK banks and a better mining sector have propelled London far into the blue Thursday. Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years. Part-nati

29 Oct 2009 12:11

FTSE 250 movers: CSR jumps as chip sales impress

CSR, which makes chips for Bluetooth and Global Positioning System (GPS) devices, is sharply higher after third quarter results were better than expected. Pre-tax profits for the period totalled $10.7m compared with a $30.8m over the same period the previous year. Revenues climbed to $219.9m from $

Latest Share Chat

EVG.L Share News (EVG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Login to your account

Quickpicks are a member only feature

Login to your account